Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy, HLX07and Serplulimab in LARC

This trial is testing a combination treatment approach for locally advanced rectal cancer — a type of colon cancer near the rectum that hasn't spread to distant organs but is in an advanced local stage. The approach combines short-course radiation, followed by chemotherapy, a targeted antibody drug (HLX07), and an immunotherapy (serplulimab), all before surgery. The goal is to shrink the tumor as much as possible before the operation. **You may be eligible if...** - You are 18–75 years old with locally advanced rectal adenocarcinoma confirmed by biopsy - Your tumor is located within 10 cm of the anal opening - Genetic testing confirms your tumor has wild-type RAS and BRAF genes (not mutated) - MRI shows high-risk features such as tumor growing through the bowel wall or into neighboring structures **You may NOT be eligible if...** - Your cancer has spread to distant organs (e.g., liver, lungs) - Your tumor has RAS or BRAF mutations - You have active autoimmune disease or a condition requiring systemic steroids - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.